Почетна › Меланом › Masachuset › Boston
Kliničke studije za Меланом u gradu Boston, MA
25 studija za Меланом traži učesnike na lokacijama u gradu Boston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Тражи се учесникФаза 1/2
- Call for Information (Investigational Site 0026), Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Тражи се учесникФаза 2
- Local Institution - 0124, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Тражи се учесникФаза 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Тражи се учесникФаза 1/2
- Tufts Medical Center, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Тражи се учесникФаза 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Тражи се учесникФаза 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Тражи се учесникФаза 2
- Massachusetts General Hospital Cancer Center, Boston
Project: Every Child for Younger Patients With Cancer
Тражи се учесникОпсервациона студија
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Тражи се учесникФаза 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Тражи се учесникФаза 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Тражи се учесникФаза 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Тражи се учесникФаза 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Тражи се учесникФаза 2
- Dana Farber Cancer Institute, Boston
Studije za Меланом u drugim gradovima
- Houston, TX61 студија
- New York City, NY41 студија
- Nashville, TN34 студија
- Los Angeles, CA34 студија
- Pittsburgh, PA31 студија
- St. Louis, MO23 студија
- Durham, NC22 студија
- Philadelphia, PA22 студија
- Tampa, FL21 студија
- Columbus, OH21 студија
- Dallas, TX21 студија
- San Francisco, CA21 студија
Ostale studije u gradu Boston
- Рак дојке110 студија
- Рак (све врсте)90 студија
- Немалоклетни карцином плућа87 студија
- Рак плућа63 студија
- Колоректални карцином62 студија
- Рак јајника62 студија
- Метастатски карцином61 студија
- Рак простате56 студија
- Карцином ендометријума51 студија
- Депресија50 студија
- Затајење срца46 студија
- Многи мијелом45 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.